CANINE ADENOVIRUS TYPE 2 STRAIN MANHATTAN - LIVE Canine Year Total Reports Total Probable Total Possible 2015 34 2 32 Presenting signs (probable and possible) Allergy (1) Haemorrhage (1) Pruritus (2) Anaphylaxis (3) Hives (1) Pulmonary oedema (1) Anorexia (3) Hypersalivation (2) Pyrexia (3) Ataxia (1) Incontinence (1) Rash (3) Behavioural change (3) Injection site reaction (2) Red eyes (1) Blisters (1) Irritation (skin) (1) Respiratory problems (1) Death (2) Lethargy (6) Site reaction (1) Defaecation (1) Lump (local) (3) Swelling (local) (1) Dermatitis (1) Nasal discharge (2) Tachycardia (1) Diarrhoea (4) Pain (3) Urticaria (1) Dyspnoea (1) Pale mucous membranes (2) Vomiting (12) Facial oedema (9) Periorbital swelling (4) CANINE CORONAVIRUS VACCINE - ANTIGEN Canine Year Total Reports Total Probable Total Possible 2015 6 0 6 Presenting signs (probable and possible) Anaphylaxis (1) Injection site reaction (1) Rash (1) Facial oedema (1) Lump (local) (1) Swelling (vulva) (1) Hives (1) Periorbital swelling (1) Vomiting (2)
CANINE ADENOVIRUS TYPE 2 STRAIN MANHATTAN - LIVE Canine Year Total Reports Total Probable Total Possible 2015 34 2 32 Presenting signs (probable and possible) Allergy (1) Anaphylaxis (3) Anorexia (3) Ataxia (1) Behavioural change (3) Blisters (1) Death (2) Defaecation (1) Dermatitis (1) Diarrhoea (4) Dyspnoea (1) Facial oedema (9) Haemorrhage (1) Hives (1) Hypersalivation (2) Incontinence (1) Injection site reaction (2) Irritation (skin) (1) Lethargy (6) Lump (local) (3) Nasal discharge (2) Pain (3) Pale mucous membranes (2) Periorbital swelling (4) Pruritus (2) Pulmonary oedema (1) Pyrexia (3) Rash (3) Red eyes (1) Respiratory problems (1) Site reaction (1) Swelling (local) (1) Tachycardia (1) Urticaria (1) Vomiting (12) CANINE CORONAVIRUS VACCINE - ANTIGEN Canine Year Total Reports Total Probable Total Possible 2015 6 0 6 Presenting signs (probable and possible) Anaphylaxis (1) Facial oedema (1) Hives (1) Injection site reaction (1) Lump (local) (1) Periorbital swelling (1) Rash (1) Swelling (vulva) (1) Vomiting (2)
40601-aerp_annual_report_2015_final.docx